BridgeBio Pharma Inc. (BBIO) Reports Q1, Provides Business Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to BridgeBio Pharma Inc. (BBIO) Reports Q1, Provides Business Update

BridgeBio Pharma Reports First Quarter 2022 Financial Results and Business Update

May 5, 2022 7:30 AM EDT

Completed sale to Sentynl Therapeutics of BridgeBios NULIBRY (Fosdenopterin) for InjectionUpdated strategic collaboration with Helsinn Group to develop, manufacture and commercialize infigratinib in oncology indications in the U.S.; BridgeBio is eligible to receive regulatory and commercial milestone payments as well as tiered royalties on adjusted net sales from HelsinnReleased positive data from Phase 2 study of BBP-418 in patients with limb-girdle muscular dystrophy type 2i (LGMD2i), which demonstrated a 43% increase in the ratio of glycosylated alpha-dystroglycan (DG) to total DG from baseline measured across all three dosing cohorts, signifying the oral... More